Shai Kalansky is an associate in the Corporate Department of Morrison & Foerster’s San Diego office and head of the Israel desk. His practice focuses on general corporate and transactional matters, including mergers and acquisitions. He assists public and private companies with a broad range of securities offerings, including registered direct offerings, PIPE transactions, underwritten deals and venture capital financings. Mr. Kalansky also provides guidance to public company clients on various disclosure and compliance related matters. He advises clients with respect to licensing matters and commercial contracts. Mr. Kalansky also counsels employers regarding employment agreements, personnel policies, and discrimination claims.
Mr. Kalansky is fluent in Hebrew and conversant in Spanish. He is on the Board of Directors of the Jewish Community Foundation of San Diego and serves on its Investment Committee.
Fulgent Genetics Initial Public OfferingRepresented Fulgent Genetics, Inc. (NASDAQ: FLGT), a comprehensive genetic testing company, as issuer’s counsel on its initial public offering.
Fulgent Genetics Preferred FinancingRepresented Fulgent Genetics, Inc. (NASDAQ: FLGT), a comprehensive genetic testing company, in its preferred stock financing of over $27 million.
Emerald Health Pharmaceuticals Regulation A+ OfferingRepresented Emerald Health Pharmaceuticals Inc., which is developing synthetic cannabinoid-derived drugs for CNS, autoimmune, and other diseases, in its Tier II Regulation A+ offering.
Cherokee Inc.’s Acquisition and Simultaneous Disposition of Hi-TecRepresented Cherokee in its acquisition of Hi-Tec Sports International Holdings B.V. and its simultaneous disposition of various operating assets in the United States, Canada, Europe and Africa. Winner of the Transatlantic Legal Award in the M&A Team of the Year (Midmarket).
Natel Engineering Company’s $280 million acquisition of OnCore ManufacturingRepresented Natel in its acquisition of OnCore Manufacturing.
Sale of BiotixRepresented the sellers of Biotix Holdings Inc. in their sale of all outstanding equity of Biotix to Mettler-Toledo, LLC.
AMN Healthcare’s $160 million acquisition of B.E. SmithRepresented AMN in its acquisition of B.E. Smith.
AMN Healthcare’s $82 million acquisition of Onward HealthcareRepresented AMN in its acquisition of Onward Healthcare.
Sale of Mo Bio LaboratoriesRepresented the sellers of Mo Bio Laboratories in their sale of all outstanding equity of Mo Bio to Qiagen.
Netlist’s public offeringsRepresented Netlist (NASDAQ: NLST), a producer of next generation persistent memory solutions, in its public offerings of common stock and warrants.
Venture CapitalRepresented technology companies in venture financings with investments by venture capital firms and strategic investors.
Imprimis Pharmaceuticals, Inc. Acquisition of Compounding PharmacyRepresented Imprimis in its acquisition of South Coast Specialty Compounding, Inc.
In re Fairfield Residential LLC, et al.Currently represent the FFR Trust, the liquidating trust that was formed to liquidate the assets of Fairfield Residential LLC, a large multi-family and low income housing developer and property manager following its chapter 11 reorganization in its disposition of its assets.
Hitachi Metals, Ltd. LicensingRepresented Hitachi Metals, Ltd. in connection with patent license agreements and settlement agreements concluded in relation to an investigation at the U.S. International Trade Commission involving infringement of certain Hitachi Metals sintered rare earth magnet patents.
©1996-2018 Morrison & Foerster LLP. All rights reserved.